Mechanism of Action (MOA)

SHINGRIX is uniquely designed to overcome age-related decline in shingles immunity1-3

The 2-dose series of the recombinant antigen/Adjuvant System formulation stimulates the immune system to generate a strong and sustained immune response.2,3,*

Image: SHINGRIX Mechanism of Action


Image: Aging Immune System

Age-related decline in immunity reduces the number and functionality of immune cells1,6-10


Image: Immune response with SHINGRIX

The antigen gE and Adjuvant System AS01B enhance VZV-specific immune response in a declining immune system1-3

VZV=varicella zoster virus.

*In a descriptive analysis of the pivotal clinical trials, the efficacy in preventing herpes zoster in adults ≥50 and ≥70 years of age was 93% and 85% respectively in the 4th year post vaccination.

Mechanism of Action Video

See how SHINGRIX helps address age-related decline in shingles immunity.1-3

You may also be interested in:

Only SHINGRIX delivered >90% efficacy against shingles regardless of age in those 50 years and older.11,

Learn about the results of 2 phase 3 clinical trials in which adverse reactions to SHINGRIX were studied.

See what CDC says about SHINGRIX.

CDC=Centers for Disease Control and Prevention.

Data from the phase 3 ZOE-50 (≥50 years of age) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.11,12. See study designs on the Efficacy page for details.